Plasma or serum: which is preferable for mutation detection in liquid biopsy?

F Pittella-Silva, YM Chin, HT Chan… - Clinical …, 2020 - academic.oup.com
Background Blood-based analysis of circulating tumor DNA (ctDNA) is a promising tool for
cancer screening, monitoring relapse/recurrence and evaluating response to treatment …
被引用次数：57 相关文章

Plasma or Serum: Which Is Preferable for Mutation Detection in Liquid Biopsy?

F Pittella-Silva, YM Chin, HT Chan… - Clinical …, 2020 - pubmed.ncbi.nlm.nih.gov
Background Blood-based analysis of circulating tumor DNA (ctDNA) is a promising tool for
cancer screening, monitoring relapse/recurrence and evaluating response to treatment …

Plasma or serum: which Is preferable for mutation detection in liquid biopsy?

F Pittella-Silva, YM Chin, HT Chan, S Nagayama… - 2020 - icts.unb.br
Background Blood-based analysis of circulating tumor DNA (ctDNA) is a promising tool for
cancer screening, monitoring relapse/recurrence and evaluating response to treatment …

Plasma or Serum: Which Is Preferable for Mutation Detection in Liquid Biopsy?

F Pittella-Silva, YM Chin, HT Chan… - Clinical …, 2020 - academic.oup.com
Background Blood-based analysis of circulating tumor DNA (ctDNA) is a promising tool for
cancer screening, monitoring relapse/recurrence and evaluating response to treatment …

Plasma or Serum: Which Is Preferable for Mutation Detection in Liquid Biopsy?

F Pittella-Silva, YM Chin, HT Chan… - Clinical …, 2020 - search.proquest.com
Background Blood-based analysis of circulating tumor DNA (ctDNA) is a promising tool for
cancer screening, monitoring relapse/recurrence and evaluating response to treatment …

Plasma or serum: which Is preferable for mutation detection in liquid biopsy?

F Pittella-Silva, YM Chin, HT Chan, S Nagayama… - 2020 - realp.unb.br
Background Blood-based analysis of circulating tumor DNA (ctDNA) is a promising tool for
cancer screening, monitoring relapse/recurrence and evaluating response to treatment …

Plasma or serum: which Is preferable for mutation detection in liquid biopsy?

F Pittella-Silva, YM Chin, HT Chan, S Nagayama… - 2020 - rlbea.unb.br
Background Blood-based analysis of circulating tumor DNA (ctDNA) is a promising tool for
cancer screening, monitoring relapse/recurrence and evaluating response to treatment …

Plasma or Serum: Which Is Preferable for Mutation Detection in Liquid Biopsy?

F Pittella-Silva, YM Chin, HT Chan… - Clinical …, 2020 - tohoku.elsevierpure.com
BACKGROUND: Blood-based analysis of circulating tumor DNA (ctDNA) is a promising tool
for cancer screening, monitoring relapse/recurrence and evaluating response to treatment …

Plasma or Serum: Which Is Preferable for Mutation Detection in Liquid Biopsy?

F Pittella-Silva, YM Chin, HT Chan, S Nagayama… - Clinical …, 2020 - europepmc.org
Background Blood-based analysis of circulating tumor DNA (ctDNA) is a promising tool for
cancer screening, monitoring relapse/recurrence and evaluating response to treatment …

[引用][C] Plasma or Serum: Which Is Preferable for Mutation Detection in Liquid Biopsy?

F Pittella-Silva, YM Chin, HT Chan, S Nagayama… - Clinical …, 2020 - go.gale.com